Biotech firm Theramir appoints Nicolas Shiacolas to board

Theramir Limited has appointed Nicolas Shiacolas to its board of directors.

Shiacolas, one of the early investors in Theramir and a seasoned member of the business community, brings significant experience and great perspective when it comes to helping young companies thrive and succeed.

As a director in the CNS Group of Companies he has served in various roles and assumed the management of several projects for the group in diverse sectors of the economy. Notably, he was, until 2020, CEO of Cablenet Communications Systems plc, where he was instrumental in expanding the start-up from a small cable TV operator back in 2006, into the hugely successful telecommunications enterprise it is today.

At Theramir, Shiacolas will apply his analytical skills and unique insight to help the cancer biotech chart a new strategic growth plan, as it seeks to partner with established pharmaceutical field players to further develop and commercialise its breakthrough microRNA based therapeutic technologies.

“I am very excited to be a part of the Theramir team formally,” said Shiacolas, of his appointment. “Theramir is a unique case where innovation will drastically change for the better, the lives of millions of people suffering from cancer.

“The opportunity to have an active role in the company and to be able to help in bringing the project to fruition for the benefit of the whole of mankind, gives me immense drive and satisfaction.”

About Theramir Limited

Theramir brings together a team of biotech entrepreneurs with significant expertise in the discovery, development and commercialisation of innovative cancer therapies.

The company focuses on the development of therapeutic agents based on stem cells and microRNA, and aims to exploit the full potential of its proprietary technology via commercial partnerships and licensing agreements with pharmaceutical industry partners, for the benefit of patients worldwide.